stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

United Therapeutics Corporation

United States · NASDAQ: UTHR · Market cap: · P/E: · P/S:

United Therapeutics sells medicines that treat a rare, dangerous form of high blood pressure in the lungs.

United Therapeutics is a drugmaker that focuses on one scary disease: pulmonary arterial hypertension, or PAH. In PAH, the small blood vessels in the lungs narrow and stiffen, so the heart has to work much harder to push blood through them. That can lead to heart failure and a much shorter life. United Therapeutics sells a family of medicines that help those blood vessels relax and keep blood flowing — Tyvaso DPI, Remodulin, Orenitram, and Adcirca — plus Unituxin, which treats a rare childhood cancer called neuroblastoma.

The business is built on a clever idea: meet patients wherever the disease is. PAH has no cure, so patients often need continuous treatment for years. United Therapeutics offers its drugs in different forms — pills, a small inhaled device, and pumps that deliver medicine under the skin or into a vein — so doctors can match the therapy to how sick a patient is and how they want to live. Remodulin, delivered through a portable pump, was the company's original breakthrough. Newer options like Tyvaso DPI, a dry-powder inhaler that patients carry around like a rescue inhaler, have become a big growth driver because they are far easier to use than older inhaled versions that required bulky machines. The money comes from selling these drugs, mostly in the United States, to patients with PAH and to the hospitals and specialty pharmacies that handle them. Because PAH is rare and the drugs are complex, competition is limited — a handful of rivals like Johnson & Johnson and Merck sell competing PAH therapies, but United Therapeutics has held a strong position by offering an unusually broad set of delivery options. Unituxin is a smaller, separate business for pediatric cancer.


One unusual thing about this company: its founder, Martine Rothblatt, is a serial entrepreneur who also founded SiriusXM satellite radio. She started United Therapeutics in the 1990s after her daughter was diagnosed with PAH, and the company has grown into a multi-billion-dollar business. It spends heavily on research, including experimental work in organ manufacturing and a potential lung transplant technology, which is a long shot but could matter enormously if it works. The company generates solid profits and uses some of that cash to buy back its own shares, which slowly shrinks the share count and gives remaining investors a bigger slice of future earnings.

Saved answer · last researched 15 Nov 2026